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Motoneuronal loss is the main feature of amyotrophic lateral sclerosis, although pathogenesis is extremely complex involving both
neural and muscle cells. In order to translationally engage the sonic hedgehog pathway, which is a promising target for neural
regeneration, recent studies have reported on the neuroprotective effects of clobetasol, an FDA-approved glucocorticoid, able to
activate this pathway via smoothened. Herein we sought to examine functional, cellular, and metabolic effects of clobetasol in a
neurotoxic mouse model of spinal motoneuronal loss. We found that clobetasol reduces muscle denervation and motor
impairments in part by restoring sonic hedgehog signaling and supporting spinal plasticity. These effects were coupled with
reduced pro-inflammatory microglia and reactive astrogliosis, reduced muscle atrophy, and support of mitochondrial integrity and
metabolism. Our results suggest that clobetasol stimulates a series of compensatory processes and therefore represents a
translational approach for intractable denervating and neurodegenerative disorders.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenera-
tive disease that affects both upper and lower motoneurons (MNs)
[1]. While relatively rare with an incidence of ~2 per 100,000, the
clinical course is severe and prognosis dismal with the vast majority
of patients dying from respiratory failure 2–5 years after diagnosis [2].
Despite extensive basic and clinical research efforts, the causes of the
disease remain to be fully elucidated and no truly effective therapies
are yet available [3, 4]. Therefore, the use of animal models
appropriately designed to recapitulate the pathology represents a
valuable tool for defining new therapeutic approaches [5].
Several data on the pathogenesis of ALS have defined a focal
origin in the central nervous system (CNS), where multiple factors
contribute to creating a toxic milieu [6, 7], but an active role of both
muscle cells and axon terminals in causing retrograde degeneration
of MNs has been also proposed as a triggering mechanism [8–10].
Consistently, during the early stages of ALS progression, muscle
undergoes denervation, and the gold standard for ALS diagnosis
remains based on nerve conduction analysis and electromyography
(EMG) [11]. In our view, the use of reductionist in vivo models would
help in the step-by-step dissection of ALS pathogenesis. To this
regard, the focal removal of confined populations of spinal MNs by
injection of cholera toxin-B conjugated to saporin (CTB-Sap), has
proven to be useful in mimicking respiratory dysfunction [12],
dysphagia [13], and focal MN loss [14, 15]. It is also worth noting that
although MN loss is certainly a critical hallmark of ALS, glial and
muscle cells are also involved [16, 17]. Neuroinflammation in ALS has
been reported to disrupt homeostatic neuroglial interactions [1].
Moreover, the onset of the disease is known to begin after
degeneration is already severe, because plastic mechanisms can
compensate for the initial MN loss [18].
Several studies reported that sonic hedgehog (SHH) may represent
a crucial regulator of neuroinflammation, neuroprotection, and
plasticity [19–22]. SHH serves as a morphogen controlling neural
tube patterning during development [23], and also self-renewal and
differentiation of neural precursor cells within the postnatal brain
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[24]. The secreted SHH ligand binds to its receptor Patched, thereby
activating smoothened (SMO); this ultimately leads to the nuclear
translocation of transcription factors Gli1–3, inducing the expression
of target genes [25]. Interestingly, SHH signaling has been shown to
play a role in ALS pathogenesis. In particular, the reduction of Gli1
has been reported within the MNs of SOD1G93A mice and SHH has
been shown to be cytoprotective in vitro [20]. Accordingly,
cerebrospinal fluid collected from ALS patients may actually inhibit
SHH signaling in vitro [26]. Therefore, SHH signaling represents a
druggable target in neurodegenerative disorders [27]. In particular,
small molecules targeting SMO have recently been explored in
cancer (i.e., SMO antagonists), stroke, and demyelinating disorders
(i.e. SMO agonists) [28, 29]. The glucocorticoid clobetasol, which also
acts as a SMO agonist, has received attention as a potential
therapeutic agent capable of remyelination and neuroprotection/
repair [30–32]. However, few data are available regarding the
potential effects of SMO activation in MN disease. Therefore, herein
we sought to examine the effects of clobetasol treatment in a murine
CTB-Sap model of MN degeneration.
RESULTS
Clobetasol promotes behavioral improvement by inducing
muscle reinnervation
We induced a spinal MN depletion by injecting CTB-Sap toxin into
the left gastrocnemius muscle (GM) and assessed the impact of
clobetasol treatment on postural and motor performance, as
compared to vehicle-treated CTB-Sap-injected mice. Clinical score
assessment showed that all animals had a rapid worsening of the
left hindlimb postural and motor ability during the first week after
lesion (Fig. 1a). Then, clobetasol-treated animals started to
ameliorate their clinical score at 14–21 days post lesion (dpl),
and this condition was retained up to 42 dpl, whereas vehicle-
treated lesioned animals did not ameliorate spontaneously (Fig.
1a). An open field grid walk test was performed in order to
evaluate the motor coordination, finding that MN ablation did not
affect the distance covered by mice during the grid walk
performance (Fig. 1b), but it significantly increased the number
of footfalls at 7 dpl as compared to healthy control (HC) group
(Fig. 1b). Notably, clobetasol reverted this impairment, promoting
a significant reduction of the number of footfalls at 21 and 42 dpl,
as compared to vehicle-treated lesioned mice (Fig. 1b).
EMG recordings from the left GM showed typical clinical
evidence of denervation, such as positive sharp waves (PSW),
fibrillation (Fig. 1c, d), pseudo-neuromyotonia (NMT, Fig. 1c–e),
and fasciculations (Fig. 1c–f). Notably, clobetasol-treated CTB-Sap-
lesioned mice showed a significant 70% reduction of PSW and
fibrillation compared to the vehicle-treated group (Fig. 1c). This
evidence was coupled with a reduced number and size of AChE-
positive spots in the left GM and a near-normal pattern in
clobetasol-treated mice (Fig. 1g). Together, these data suggest
that clobetasol exerts restorative behavioral effects and promotes
muscle reinnervation after neurotoxic MN removal.
Clobetasol promotes spinal cord plasticity acting on SHH
signaling pathway
Neuropathological assessment of lumbar spinal cord sections
revealed a depletion of about 50% of MNs in the lesioned (i.e. left)
side compared to the intact spinal cord side (Fig. 2a–c), and this rate
of MN loss was present in all CTB-Sap-lesioned mice, regardless of the
drug treatments. This suggests that the functional amelioration and
muscle reinnervation is linked to compensatory plastic changes
within the spared MN population.
In order to link our observations with a potential activation of the
SHH signaling pathway in the spinal cord, we analyzed Gli1 nuclear
translocation in resident cell populations of HC and CTB-Sap mice
treated with either vehicle or clobetasol. Results showed that the
total fluorescence intensity (FI) of Gli1 was unchanged (Fig. 2d),
whereas a significant reduction of nuclear Gli1 FI was found in CTB-
Sap-lesioned mice at 42 dpl, but near-normal levels were found in
CTB-Sap mice treated with clobetasol (Fig. 2e). To analyze such a
modulation into specific cell populations, we evaluated the Gli1
nuclear translocation in NeuN (i.e. neurons), Gfap (i.e. astrocytes), and
Iba1 (i.e. microglia) positive cells. Our data highlighted that clobetasol
was able to significantly increase the amount of nuclear Gli1 in
NeuN-positive cells by about 2 folds (Fig. 2f, g). Moreover, a reduction
of nuclear Gli1 was found in the astroglial cell population after lesion
but, importantly, near-normal levels were present in clobetasol-
treated mice (Fig. 2f–h). Finally, neither CTB-sap lesion nor clobetasol
treatment did affect nuclear translocation of Gli1 in microglia (Fig.
2f–i). We also analyzed the potential effect of clobetasol in
modulating spinal MN plasticity. Lesioned animals treated with
clobetasol showed a remarkable increase of newly formed synaptic
contacts labeled with synaptophysin, as compared to both vehicle-
treated lesioned mice and HC (Fig. 2j).
Clobetasol modulates metabolic changes in MN-depleted
spinal cord
We examined the metabolic profiles of the intact and lesioned spinal
cord either with or without clobetasol treatment (Figs. S1 and S2).
Our results suggest that amino acids biosynthesis metabolic path-
ways (Fig. 3a–c), lysine, tryptophan, and arginine levels were
significantly modulated in CTB-Sap clobetasol versus CTB-Sap vehicle
mice (Fig. 3d). We also observed that isoleucine levels were slightly,
but not significantly, reduced in CTB-Sap vehicle group and
significantly decreased in CTB-Sap clobetasol mice (Fig. 3d). Among
the highest contributors to the PCA analysis (Fig. S2) we found that
hypoxanthine and xanthine were of importance and they were
significantly higher in CTB-Sap vehicle mice (Fig. 3d), while clobetasol
reverted such accumulation to the level of healthy spinal tissue (Fig.
3d). Results also revealed that CTB-Sap lesion was associated with a
reduction of GABA and glycine, both involved in spinal inhibitory
circuitry and that clobetasol was able to restore near-normal levels of
both neurotransmitters (Fig. 3d). Interestingly, even in presence of a
reduced number of MNs in the lesioned spinal cord side (about 50%),
no significant changes were observed in glutamate levels (Fig. 3d),
thus suggesting that spared MNs could probably receive increased
glutamate signaling as compared to HC MNs.
Clobetasol reduces pro-inflammatory resident cells in MN-
depleted spinal cord
MN ablation was associated with an increased total number of
Gfap+ astrocytes in the Rexed lamina IX of CTB-Sap-lesioned mice
treated with vehicle, whereas clobetasol-treated group showed an
apparent but not statistically significant increase over control
levels (Fig. 4a, b). However, the total Gfap mRNA levels measured
in the spinal cord were similar in both lesioned groups, with a
significant increase above control levels (Fig. 4c). In order to clarify
whether spinal astrocytes were polarized towards a reactive state,
we analyzed phospho-stat-3 (P-Stat3) expression in spinal Gfap+
cells (Fig. 4d). Our evidence supports the hypothesis that MN
depletion increases the number of reactive astrocytes, and that
clobetasol was able to reduce nuclear P-Stat3 expression in lamina
IX, thus partially reversing the effects of the lesion.
We also performed a multidimensional flow cytometry analysis
of spinal cord samples to characterize the myeloid compartment
(i.e. tissue-resident microglia phenotypes, monocytes, monocytes-
derived macrophages) and, due to shared markers, also B and
non-B (i.e. T NK) lymphocytes (Fig. S3). Interestingly, our results
showed that MN depletion increased the frequency of CD206+
and CD80+ inflammatory microglia and that clobetasol, besides
reducing polarized microglial cells (Fig. 4e, f), also reduced the
total amount of B and T NK lymphocytes (Fig. 4e, f). These findings
suggest that clobetasol was able to attenuate the pro-
inflammatory signaling in the spinal cord, thus likely promoting
plasticity and compensatory processes.
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Fig. 1 Clobetasol ameliorates behavioral impairment of CTB-Sap-induced MN ablation. a Repeated measures of a clinical score of motor
impairment during the time-course of CTB-Sap-induced motoneuronal depletion in CTB-Sap vehicle and CTB-Sap clobetasol groups; data are
shown as mean ± SEM of n= 12 mice per group; *p-value < 0.05 and **p-value < 0.01 between groups; two-way repeated-measures ANOVA.
b Representative tracks of HC, CTB-Sap vehicle, and CTB-Sap clobetasol groups and quantification of the distance (expressed as mean meters
± SEM of n= 5 mice per time-point, as repeated measures) covered during 2min performance on open-field grid walk test and quantification
of the number of footfalls over a meter at −1, 7, 21 and 41 dpl in HC, CTB-Sap vehicle, and CTB-Sap clobetasol groups; data are shown as
standard box-and-whiskers of n= 5 mice per group; *p-value < 0.05 and **p-value < 0.01 versus HC and between groups; two-way repeated-
measures ANOVA. c–f Quantification and representative electromyographic profile of positive sharp waves (PSW, c and d), fibrillations (c and
d), pseudo-neuromyotonia (NMT, c and e), and fasciculations (c and f) observed in denervated GM in CTB-Sap vehicle (black tracks in d–f) and
CTB-Sap clobetasol groups (gray tracks in d–f); data are expressed as a number of events per second and showed as standard box-and-
whiskers of n= 4 mice per group; measures were taken from distinct samples; *p-value < 0.05 versus CTB-Sap vehicle; two-sided Student’s t-
test. g Representative pictures of AChE immunostaining and hematoxylin (HMX) and negative control (NC) on left GM of HC, CTB-Sap vehicle,
and CTB-Sap clobetasol; scale bar: 25 μm. Dpl: days post lesion.
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Clobetasol promotes trophic processes in the denervated
muscle
In order to associate the CNS effects induced by clobetasol with the
observed functional restoration, we analyzed the morphological and
metabolic changes of muscles. Our data indicate that, after the partial
denervation caused by MN removal, muscle fibers in GM showed an
increased number of centrally located nuclei (CLN) as compared to
HC (Fig. 5a, b), but clobetasol treatment significantly reduced the
proportion of myofibers with CLN (Fig. 5b). To assess muscle atrophy,
we evaluated the cross-sectional area of myofibers in GM of CTB-Sap
mice treated with vehicle or clobetasol, finding an overall increase of
fiber area in clobetasol-treated mice compared to vehicle-treated,
even if it did not reach the physiological pattern found in HC mice
(Fig. 5a–c). Such an amelioration was coupled with increased Pax7+
cells in GM of clobetasol-treated mice (Fig. 5d). Furthermore, we
found a significantly increased amount of F4/80+ infiltrating
macrophages in both vehicle-treated and clobetasol-treated dener-
vated muscles (Fig. 5e, f). To determine the phenotype of infiltrating
macrophages in GM of vehicle-treated and clobetasol-treated mice,
we analyzed F4/80+ cell phenotype (Fig. 5g) by quantifying those
highly expressing iNos or Arg1. The results revealed that clobetasol
was able to significantly increase the proportion of anti-inflammatory
infiltrating macrophages into denervated GM (Fig. 5g, h), thus likely
sustaining a pro-regenerative microenvironment. Finally, we analyzed
the metabolic effects induced by denervation onto GMs (Fig. S4–S6).
PCA analysis revealed that inosine monophosphate (IMP),
Fig. 2 Clobetasol modulates Gli1 nuclear translocation and plasticity on MN-depleted spinal cord. a–c Quantification of the number of
motoneurons in left (L) and right (R) Rexed lamina IX in HC, CTB-Sap vehicle and CTB-Sap clobetasol groups (a) and representative pictures of
spinal cord sections stained with cresyl violet of CTB-Sap vehicle (b) and CTB-Sap clobetasol (c); data in (a) are expressed as the ratio of L over
R motoneurons number ± SEM (shade) of n= 8 sections of n= 5 mice per group; *p-value < 0.05 versus HC; one-way ANOVA; scale bar in (b)
and (c): 200 μm. d and e Quantification of the total Gli1 fluorescence intensity (FI) over μm (d) and of the percentage of high nuclear FI of Gli1
(e) in HC, CTB-Sap vehicle, and CTB-Sap clobetasol spinal cord cell population; data are shown as scatter dot plots and mean ± SEM of n ≥ 3
mice per group; *p-value < 0.05 versus HC and between groups; one-way ANOVA. f–i Representative pictures and quantification of the
proportion of NeuN positive (f and g), Gfap positive (f and h), and Iba1 positive (f and i) cells with high nuclear FI of Gli1 in HC, CTB-Sap
vehicle, and CTB-Sap clobetasol spinal cord; data are shown as scatter dot plots and mean ± SEM of n ≥ 3 mice per group; *p-value < 0.05 and
**p-value < 0.01 versus HC and between groups; one-way ANOVA. j Representative pictures of NeuN and Synaptophysin immunofluorescence
on spinal cord motoneurons of HC, CTB-Sap vehicle, and CTB-Sap clobetasol; scale bar: 20 μm.
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hypoxanthine, xanthine, and uric acid played a major role. This
analysis also highlighted that purine nucleotide catabolism and fatty
acid biosynthesis and elongation were strictly regulated in dener-
vated GM (Fig. 5i). We observed a robust accumulation of IMP,
hypoxanthine, xanthine, and uric acid in CTB-Sap vehicle group (Fig.
5j, k), which suggests an overproduction of reactive oxygen species
in the muscular microenvironment, and a decreased availability of
malonil-CoA for fatty acid biosynthesis (Fig. 5j). Such evidence
suggests that denervation shapes purine and fatty acid metabolism
in the muscle and that clobetasol was able to revert this condition
(Fig. 5j), promoting favorable metabolic programs after CTB-Sap-
induced muscle denervation.
Clobetasol reverts denervation-induced mitochondrial fission
and increases energy substrates
Mitochondrial morphology was assessed in muscle sections,
finding that denervation strongly affected mitochondrial fitness,
as shown by the significant reduction of mitochondrial length (Fig.
6a, b) and by the significant increase of dynamin-like 1 (Dnm1l)
mRNA levels, which is an essential gene controlling mitochondrial
fission (Fig. 6c). Notably, clobetasol-treated CTB-Sap-lesioned mice
showed increased mitochondrial length, coupled with a normal-
ization of Dnm1l mRNA levels (Fig. 6a–c), suggesting a restored
mitochondrial homeostasis and energy metabolism in clobetasol-
treated mice. Then, we analyzed phosphate nucleotides, nicotinic
coenzymes, and glycosylated UDP-derivatives (Fig. 6d and Fig. S7).
The results highlighted a significant accumulation of glycosylated
UDP-derivatives and monophosphate nucleotides coupled with a
reduction of ATP in GM of CTB-Sap mice treated with vehicle (Fig.
6e), and these effects were reverted by clobetasol (Fig. 6f). Indeed,
UDP-Gal, UDP-GalNac, UDP-Glc, and UDP-GlcNac (Fig. 6g), were all
significantly increased in CTB-Sap-vehicle mice, whereas clobeta-
sol treatment induced their normalization (Fig. 6g).
Notably, by measuring the levels of nicotinic coenzymes, we found
a strong decrease of the oxidized over reduced form of NAD and
NADP, thus indicating a reduced mitochondrial redox potential in
denervated GM as compared to HC and clobetasol-treated lesioned
group (Fig. 6g). Finally, we evaluated the ratio between ATP and ADP
and the energy charge potential (ECP). Our data highlighted an
overall increase of ATP/ADP ratio and ECP induced by clobetasol
versus vehicle group (Fig. 6g), thus supporting the hypothesis of
restored energy metabolism.
Human ALS spinal cord shows impaired SHH signaling
pathway
In order to evaluate the potential involvement of SHH signaling
pathway in human ALS patients, we first performed a z-score
analysis of a selected dataset containing mRNA expression data
from spinal cord biopsies of n= 10 HC subjects and n= 10 ALS
patients. Despite similar SHH mRNA expression levels (Fig. 7a), we
found a significant reduction of PTCH1 mRNA levels in the spinal
cord of ALS patients (Fig. 7b). Notably, this reduction was not
coupled with a reduction of SMO mRNA levels (Fig. 7c), but it was
coupled with reduced mRNA levels of SHH-signaling pathway
effector GLI1 (Fig. 7d). This would suggest that SHH signaling
pathway may represent a promising target for pharmacological
treatment of MN diseases using SMO agonists.
Moreover, the interaction network of SHH signaling pathway
genes SHH, PTCH1, SMO, GLI1, GLI2, and GLI3 showed significant
interactions, based on available databases or experimentally
Fig. 3 Clobetasol modifies spinal cord metabolism and relevant neurotransmitters. a and b Summary plot for pathway analysis (a) and
quantitative enrichment analysis (b) for metabolites levels in CTB-Sap vehicle versus CTB-Sap clobetasol; c Schematic representation of amino
acids biosynthesis showing significantly upregulated (green) and downregulated (red) metabolites in CTB-Sap clobetasol versus CTB-Sap
vehicle group. d Metabolites levels in the spinal cord of HC, CTB-Sap vehicle and CTB-Sap clobetasol mice; data are shown as mean ± SEM and
scattered dot plots of n= 4 mice per group; *p-value < 0.05, **p-value < 0.01, ****p-value < 0.0001 versus HC or between groups; one-
way ANOVA.
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determined in humans, between the six selected genes (i.e. query)
and the top-20 interactor genes (Fig. 7e). Enrichment KEGG analysis
revealed significant modulation of pathways involved in chemokine
signaling, axon guidance, synapses, and neurotransmission (Fig. 7f),
thus supporting the idea that SHH modulation holds great relevance
in human CNS homeostasis and compensatory processes.
DISCUSSION
Several studies have shown that alterations of spinal cord circuitries
and MNs can start far earlier than the onset of symptoms [33, 34].
This suggests that compensatory changes occur in an attempt to
maintain neuromuscular functions despite the progressive loss of
motor units, and the possibility to target this plasticity coupled with
Fig. 4 Clobetasol-mediated reduction of pro-inflammatory cells in MN-depleted spinal cord. a and b Representative pictures of Gfap
immunostaining (a) and quantification of the number of positive cells for Gfap (b) in HC, CTB-Sap vehicle, and CTB-Sap clobetasol spinal cord;
data are shown as scatter dot plot and mean ± SEM of n ≥ 3 mice per group; *p-value < 0.05 versus HC; one-way ANOVA; scale bar in (a): 25 μm.
c mRNA levels of Gfap in the spinal cord of in HC, CTB-Sap vehicle, and CTB-Sap clobetasol spinal cord; data are shown as standard box-and-
whiskers plot and mean ± SEM of n ≥ 3 mice per group; **p-value < 0.01 versus HC; one-way ANOVA. d Representative pictures and confocal
deconvolutions of Gfap and P-Stat3 staining in HC, CTB-Sap vehicle, and CTB-Sap clobetasol spinal cord; arrowheads indicate astrocytes nuclei
and in CTB-Sap vehicle P-Stat3 positive nuclei; scale bar: 20 μm. e Uniform manifold approximation and projection (UMAP) representation of
the populations identified through flow-cytometry in the three different conditions. f Standard box-and-whiskers plot representing the five
subpopulations that presented a significant modulation between HC, CTB-Sap vehicle, and CTB-Sap clobetasol mice. Plots show data from
n= 4 mice per group; *p-value < 0.05 versus CTB-Sap vehicle; one-way ANOVA.
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efficient methods of early diagnosis would increase the chances of
delaying the disease progression and hopefully promoting repair.
Although genetic mouse models of ALS are necessary to model the
human disease, reductionist animal models, such as the CTB-Sap
model, are useful to dissect specific pathogenic mechanisms, since
they are able to mimic a limited and controlled series of disease
features. In our CTB-Sap model of spinal MN removal, the severity of
the lesion and, as a consequence, the capability of self-restoration,
can be modulated simply by choosing different doses of CTB-Sap.
After administration of relatively low doses of toxin, mice were able
to recover as soon as 4–6 weeks after the lesion [15]. Increased
activity in the spared MNs and surrounding circuitries, likely driven by
synaptic plasticity, could be responsible for these compensatory
changes with possible involvement of SHH [35, 36].
In the present study, in order to test the effects of modulating the
SHH pathway by the SMO agonist clobetasol, we used a dose of CTB-
Sap able to ablate about 50% of resident MNs, and inducing a stable
motor impairment, without any spontaneous amelioration up to
6 weeks post-lesion. The effects of clobetasol treatment were then
evaluated from functional, metabolic, and pathophysiological
N. Vicario et al.
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aspects. After CTB-Sap injection, animals developed a rapid motor
impairment of the affected hindlimb during the first week and these
deficits appeared very stable during the entire experimental time-
course in vehicle-treated animals. Interestingly, when animals were
treated with clobetasol, a significant improvement of behavioral
signs was observed as early as 3 weeks post-lesion and animals
became able to near-normal walking.
These effects were coupled with reduced muscle denervation in
clobetasol-treated mice. The post-mortem analysis of the spinal cord
revealed a down-regulation of synaptophysin expression by the
spared lumbar MNs, suggesting a decreased number of synapses on
their somata after removal of neighboring MNs. Interestingly,
lesioned animals treated with clobetasol showed an increased
expression of synaptophysin, which is supposed to be linked to MN
plasticity and functional restoration. Accordingly, the quantitative
analysis of spinal cord metabolites has revealed a decrease of the
inhibitory neurotransmitters GABA and glycine in lesioned animals.
Moreover, although the level of glutamate was unchanged in the
lumbar spinal cord after the lesion, we should consider that it acts
onto a reduced population of MNs. Taken together, these findings
suggest an attempt of spinal cord circuitries to compensate for the
decreased neuromuscular activity, and the restoration of GABA and
glycine levels after clobetasol treatment can suggest a rebalancing of
neuronal activity promoted by the drug. Other critical aminoacids
were affected by both MN removal and SMO modulation. Among
them, we found significant alterations of lysine, tryptophan, arginine,
and isoleucine, suggesting profound metabolic changes in the
lesioned and treated spinal cord, involving glycolysis and tricar-
boxylic acid cycle. These changes are also present in patients, as well
as in ALS experimental models [37, 38].
Our observation of astrocytes and microglial modulation is in line
with increased levels of hypoxanthine and xanthine, the conversion
of which produces a significant accumulation of reactive oxygen
species. This could represent a major cause of neuronal suffering and
it is also the rationale for edaravone treatment of ALS patients [39].
Notably, our results demonstrate that clobetasol is also able to
reduce immune response not only modulating astrocytes and
microglia polarization but also attenuating B and T NK lymphocyte
infiltration.
The analysis of muscle also showed profound changes after
CTB-Sap-induced denervation and as a result of treatment with
clobetasol. Denervated GMs appeared atrophic but, interestingly,
a five-fold increase of the number of CLN was detected in muscle
sections, thus suggesting an attempt of regeneration [40]. The
regenerative potential of the denervated muscle was boosted by
administration of clobetasol, as demonstrated by the increased
expression of Pax7 and by the increased cross-sectional area of
muscle fibers, together with the reduction of CLN in comparison
to the lesioned and vehicle-treated muscle. Taken together, the
observed changes of GM morphology indicate that clobetasol may
accelerate the muscle repairing processes.
The effect of CTB-Sap injection on muscle metabolism was
observed in most of the metabolites under evaluation. A dramatic
decrease in the ATP/ADP ratio, ECP, NAD+/NADH ratio, NADP+/
NADPH ratio, concomitantly accompanied by an increase in
oxypurines (hypoxanthine, xanthine, uric acid), IMP, nitrite, and
nitrate, are clear indicators of mitochondrial dysfunction, also
suggested by increased mitochondrial fission, with an imbalance in
ATP production and consumption, consequent energy stress, the
compensatory metabolic shift towards oxygen-independent glucose
consumption through glycolysis, and oxidative/nitrosative stress with
decreased antioxidant defenses. Among the various alterations of cell
metabolism, those occurring to UDP-derivatives are certainly the
most evident. The higher values of nucleotide sugars strongly
suggest that the hexosamine biosynthetic pathway, representing the
key process for the post-translational protein glycosylation, is highly
active in damaged muscle. This finding may be indicative either of
increased production of myokines or fibro/adipogenic processes,
both being also reported as ALS-linked skeletal muscle changes
[41, 42].
We hypothesize that clobetasol, acting as a glucocorticoid, could
mobilize fatty acids and we found that, in denervated muscle,
reduced malonil-CoA levels were present. Indeed, clobetasol was
able to revert this phenomenon increasing fatty acid metabolism.
Such results are in line with previously published reports linking
hypolipidemia and dyslipidemia with ALS progression [43, 44].
Taken together, our data suggest that clobetasol exerts a
pleiotropic effect in both the spinal cord and muscle finally
resulting in neuromuscular plasticity. We can draw a number of
conclusions from these observations. First, MNs depletion is
associated with behavioral impairment and substantial neuro-
muscular alterations ranging from metabolic changes to the
activation of immune response in the spinal cord, and from critical
myopathy to energetic imbalance in the muscle. Second, the
multitarget drug clobetasol acts by increasing Gli1 nuclear
translocation in spinal astrocytes and spared MNs, reverting the
known canonical SHH reduction that we observed in our
experimental model of denervation [14, 36]. Third, robust
inhibition of muscular fatty acid metabolism was observed in
denervated mice and such a reduction was reverted by clobetasol.
In summary, these results confirm the existence of significant
capacity of neuromuscular plasticity, which can be manipulated by
drugs affecting a number of targets, including metabolism, reactive
neuroglia and CNS infiltrating lymphocytes, synaptic plasticity, and
muscle regeneration. Among these targets, particular attention
should be paid to the SHH signaling, also in relation to MN diseases.
The existence of an already approved drug-like clobetasol acting
onto this pathway increases the interest in this promising potential
therapeutic approach in ALS.
Interestingly, our work highlighting the role of SHH pathway in
human ALS patients, suggests that the described results could be
relevant for human ALS. Further studies also including SMO
Fig. 5 Clobetasol increases muscle fiber size and metabolism. a Representative pictures of H&E staining in left GM of HC, CTB-Sap vehicle,
and CTB-Sap clobetasol mice; scale bar: 25 μm. b Quantification of the percentage of centrally located nuclei (CLN) in HC, CTB-Sap, and CTB-
Sap clobetasol-treated mice; data are % of CLN over total muscle fibers and are shown as scatter dot plot and mean ± SEM of n ≥ 3 mice per
group; ***p-value < 0.001 versus HC or between groups; one-way ANOVA. c Frequency plot of the mean fiber cross-sectional area expressed in
μm2 in the left GM of CTB-Sap vehicle and CTB-Sap clobetasol mice. d Representative pictures of Pax7 positive cells in the left GM of CTB-Sap
vehicle and CTB-Sap clobetasol mice. e and f Quantification of the percentage of F4/80 positive area per section (e) and representative
pictures of F4/80 immunostaining (f) in the left GM of HC, CTB-Sap vehicle, and CTB-Sap clobetasol mice; data in (e) are shown as scatter dot
plot and mean ± SEM of n ≥ 3 mice per group; *p-value < 0.05 and **p-value < 0.01 versus HC; one-way ANOVA; scale bar in (f): 25 μm. g and h
Representative pictures of F4/80, iNos and Arg1 immunostaining (g) and quantification of the FI of iNOS and Arg1 in F4/80 positive cells (h) in
the left GM of CTB-Sap vehicle and CTB-Sap clobetasol mice; data in (h) are shown as scatter dot plot and mean ± SEM of n ≥ 3 mice per group;
**p-value < 0.01 versus CTB-Sap vehicle; two-sided Student’s t-test. Scale bar in (g): 25 μm. i Summary plot for quantitative enrichment analysis
and pathway analysis for metabolites levels in CTB-Sap vehicle versus CTB-Sap clobetasol; j Metabolites levels in the left GMs of HC, CTB-Sap
vehicle, and CTB-Sap clobetasol mice; data are shown as mean ± SEM and scattered dots plot of n= 4 mice per group; *p-value < 0.05 and **p-
value < 0.01 versus HC or between groups; one-way ANOVA. k Schematic representation of purine metabolism showing significantly
upregulated metabolites in red in CTB-Sap vehicle versus CTB-Sap clobetasol group.
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Fig. 6 Clobetasol reverts denervation-induced mitochondrial fission and increases energy substrates. a and b Representative pictures of
MitoTracker immunostaining (a) and quantification of the mitochondrial length expressed in μm (b) in the left GM of HC, CTB-Sap vehicle, and
CTB-Sap clobetasol mice; data in (b) are shown as scatter dot plot and mean ± SEM of n ≥ 3 mice per group; *p-value < 0.05, **p-value < 0.01
and ***p-value < 0.001 versus HC or between groups; one-way ANOVA; scale bar in (a): 25 μm. c mRNA expression levels of Dnm1l in the left
GM of HC, CTB-Sap vehicle and CTB-Sap clobetasol mice; data are fold changes over HC and are shown as standard box-and-whiskers plot of
n= 5 mice per group; *p-value < 0.05 versus HC or between groups; one-way ANOVA. d Heat maps of 24 metabolites in the left GM HC, CTB-
Sap vehicle and CTB-Sap clobetasol at 42 dpl showing the abundance (Ab.) in HC and the relative changes in CTB-Sap vehicle and CTB-Sap
clobetasol as compared to HC; data are shown as log10 abundance and log2 FC over HC of n= 4 mice per group. e and f Volcano plots of
metabolites levels in HC versus CTB-Sap vehicle (e) and CTB-Sap vehicle versus CTB-Sap clobetasol (f). gMetabolites levels and ratios in the left
GMs of HC, CTB-Sap vehicle, and CTB-Sap clobetasol mice; data are shown as mean ± SEM and scattered dots plot of n= 4 mice per group;
*p-value < 0.05 and **p-value < 0.01 versus HC or between groups; one-way ANOVA.
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agonists in other animal models might provide additional
evidence about the potential bench-to-bedside translation of
the findings described here.
MATERIALS AND METHODS
Animal model
All experiments were performed in accordance with the principle of the Basel
Declaration as well as to the European and Italian regulations (2010/63/EU and
Italian D. Lgs. no. 26/2014). All efforts were made to replace, reduce and refine
the use of laboratory animals. Moreover, the study was conducted in
accordance with the recommendations of the local committee for animal
welfare (OPBA, University of Catania, Catania, Italy); the protocol was approved
by OPBA and by the Italian Ministry of Health. 48 male 129S1/SvImJ (Jackson
Laboratory), 8–12 weeks old and weighing 25.6 ± 0.4 g were used. Animals
were randomly assigned to different cages (n≤ 5 animals per cage) and kept
under constant temperature (23−25 °C) with ad libitum access to food and
water. Mice were divided into three groups: HC group (no injection, n= 16),
CTB-Sap clobetasol (injected with CTB-Sap and then treated with clobetasol
propionate, n= 16), and CTB-Sap vehicle group (injected with CTB-Sap and
then treated with drug vehicle only, n= 16). CTB-Sap injection was performed
as previously described [45, 46]. Briefly, mice were anesthetized with isoflurane
(4% for induction, 2% for maintenance) and then received two injections of the
ribosome-inactivating and retrogradely transported toxin CTB-Sap (Advanced
Targeting Systems, San Diego, CA, USA) into the medial and lateral left
gastrocnemius with a toxin dose of 6 μg/2 μL in PBS per injection. Subgroups
of CTB-Sap lesioned mice received an intraperitoneal injection of either
clobetasol propionate (4mg/kg) or vehicle alone, 7 days post lesion (dpl).
Treatments were repeated once a week at 14, 21, 28, and 35 dpl.
Behavioral impairment was evaluated by two separate observers blind to
the treatment analyzing the hind limb posture and gait capability, and
assigning a clinical score in accordance with the following criteria described
by Albano et al. [47, 48]. Animals were sacrificed at 42 dpl by intracardial
perfusion and organs, i.e. spinal cords and GMs were dissected out, post-fixed,
embedded in OCT or paraffin, respectively, and sectioned using a cryostat or a
microtome.
Open field grid walk test
Open field grid walk test for motor coordination impairment was
performed at 7, 21, and 42 dpl using a “tracking camera” placed above
the open field, to record and quantify the distance covered by every
animal and a “counting camera”, placed in line with the grid, to
quantify the number of footfalls within 2 min. For each performance,
each animal was placed in a 40 × 40 cm grid (each mesh 1 cm2) and was
free to move and explore during the behavioral test. The tracking and
the counting videos were analyzed offline using Ctrax tracker software
version 0.5.18 for Mac.
Electromyography
EMG analysis was performed at 42 dpl using a portable two-channel EMG
device (Myoquick, Micromed S.p.A., Mogliano Veneto, Treviso, Italy) with
one bipolar concentric needle electrode inserted in the left GM and
one ground electrode. Animals were anesthetized with isoflurane before
the electromyographic recording. The spontaneous electrical activity of the
muscle was recorded and then analyzed using System PLUS Evolution
software by Micromed S.p.A. (Mogliano Veneto, Treviso, Italy).
mRNA analysis
For quantification of mRNA levels of Dnm1l and actb in muscle, we used
the QuantiGene Plex Magnetic Separation Assay kit (Affymetrix, Santa
Clara, CA, USA) following the manufacturer’s instructions and as previously
described [32]. The signal was detected with a Luminex instrument (Bio-
Rad, Milan, Italy). For each sample, the average signal (MFI) for Dnm1l and
actb were determined and, after average background signal subtraction,
Dnm1l signal was normalized to the housekeeping gene signal.
Fig. 7 SHH signaling pathway is downregulated in ALS. a–d Analysis of SHH (a), PTCH1 (b), SMO (c), and GLI1 (d) expression levels in spinal
cord biopsies of human healthy control (HC) and ALS patients; data are shown as standard box-and-whiskers of n= 10 HC and n= 10 ALS
subjects; *p-value < 0.05 versus HC; two-sided Student’s t-test. e Interaction network of six selected genes (i.e. query) of SHH signaling pathway
(in red) and the top-20 interactors genes (in white); interactions are shown as based on curated databases (red lines) or experimentally
determined (black lines). f Enrichment KEGG analysis of genes showed in panel (e); significant pathways related to SHH signaling in humans
are shown as −log of false discovery rate (FDR).
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Immunohistochemistry
Rehydrated sections were subjected to a standard protocol of immuno-
histochemistry. Both muscle and spinal cord sections were subjected to a
protocol of antigen retrieval (for AChE, Gfap and F4/80 staining) using an
antigen retrieval buffer (0,1% Tween 20 in citrate buffer solution) and
heating in microwave (5 min per 3 cycles). After samples were blocked with
3% H2O2 in PBS for 15min at room temperature in a humidity chamber,
they were washed in PBS and incubated for 40min at room temperature in
a humidity chamber with the following primary antibodies diluted in 0.3%
Triton X100 in PBS: rat monoclonal anti-F4/80 (Bio-Rad, Cat#MCA497R,
RRID: 323279, 1:100), rabbit monoclonal anti-AChE (Abcam, Cat#ab240274,
RRID: AB_2857345,1:50), mouse monoclonal anti-GFAP (BD Biosciences,
Cat#610566, RRID: AB_397916, 1:100). Then, samples were washed in 0.3%
Triton in PBS three times for 5 min and incubated with pre-diluted
biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) and
with R.T.U. VECTASTAIN Elite ABC Reagent (Vector Laboratories) for 30min
at room temperature in a humidity chamber, respectively. Samples were
then washed in 0.3% Triton X100 in PBS for 5 min and exposed to a
solution of 1% DAB, 0.3% H2O2 in PBS. Nuclei were counterstained with
Mayer’s hematoxylin (Bio-Optica), dehydrated with increasing concentra-
tion of ethanol (70%, 95%, 100%) and xylene, and coverslipped with
Entellan (Merck, Cat# 1.079.600.500).
For the analysis of GFAP by immunohistochemistry on the spinal cord,
sections were counterstained with cresyl violet staining, dehydrated with
the same procedure above and coverslipped with BrightMount (Aqueous
Mounting Medium for Fluorescent Staining, Abcam, Cat#ab103746).
For neuronal or muscle fiber staining, spinal cord and muscle sections
were stained with cresyl violet or hematoxylin/eosin, respectively.
For quantification of the number of GFAP positive cells, muscle fibers
diameter distribution, CNL and F4/80 positive cells, n ≥ 3 equally spaced
sections of the spinal cord or GM were analyzed and quantified by
operators blind to the treatment using an Olympus BH2 microscope and
Olympus CAST GRID software.
Immunofluorescence
After antigen retrieval procedure as described above, sections were incubated
with 10% NGS in PBS–0.3% Triton for 1 h at room temperature and then
overnight at 4 °C with an appropriate combination of one of the following
antibodies diluted in 1% NGS in PBS and 0.3% Triton. For spinal cord staining:
rabbit polyclonal anti-Gli1 (Abcam, Cat#ab49314, RRID: AB_880198, 1:100);
mouse monoclonal anti-NeuN (Millipore, Cat#MAB377, RRID: AB_2298772,
1:100); mouse monoclonal anti-GFAP (BD Biosciences, Cat# 610566, RRID:
AB_397916, 1:500); goat polyclonal anti-AIF1/IBA1 (Novus, Cat# NB100-1028,
RRID: AB_521594, 1:100); rabbit polyclonal anti-SYP (Santa Cruz Biotechnology,
Cat#sc-9116, RRID: AB_2199007, 1:50); rabbit monoclonal anti-P-Stat3 (Cell
signaling Technology, Cat# 9145, RRID: AB_2491009, 1:200). For muscle
staining: mouse monoclonal anti-PAX7 (Abcam, Cat# ab199010, RRID: N.A.,
1:250); rat monoclonal anti-F4/80 (Bio-Rad, Cat# MCA497R, RRID: AB_323279,
1:50); mouse monoclonal anti-iNOS (Santa Cruz Biotechnology, Cat# sc-7271,
RRID: AB_627810, 1:50); rabbit polyclonal anti-ARG1 (Santa Cruz Biotechnol-
ogy, Cat# sc-20150, RRID: AB_2958955, 1:50); mouse monoclonal anti-DRP1
(BD Biosciences, Cat# 611112, RRID: AB_398423, 1:100). Samples were then
washed and incubated for 1 h at room temperature with appropriate
secondary antibodies diluted 1:1000 in 1% NGS in PBS and 0.3% Triton:
donkey anti-goat (Alexa Fluor 488, ThermoFisher Scientific, Cat#A-11055, RRID:
AB_2534102 or Alexa Fluor 546, ThermoFisher Scientific, Cat#A-11056, RRID:
AB_142628); goat polyclonal anti-rabbit (Alexa Fluor 488, Molecular Probes,
Cat#A-11008, RRID: AB_143165; Alexa Fluor 546, Molecular Probes, Cat# A-
11010, RRID: AB_2534077; Alexa Fluor 647, ThermoFisher Scientific, Cat#A-
21244, RRID: AB_2535812); goat polyclonal anti-mouse (Alexa Fluor 488,
ThermoFisher Scientific, Cat# A-11001, RRID: AB_2534069; Alexa Fluor 546,
Molecular Probes, Cat#A-11003, RRID: AB_141370; Alexa Fluor 647, Thermo-
Fisher Scientific, Cat# A-21235, RRID: AB_2535804); goat anti-rat (Alexa Fluor
488, Molecular Probes, Cat# A-11006, RRID: AB_141373). Nuclei were
counterstained with DAPI 1:1000 in PBS. Slides were coverslipped with
BrightMount (Abcam, Cat#ab103746).
For quantification of Gli1 fluorescence intensity (FI), Gli1 nuclear FI, iNOS
FI, Arg1 FI, and mitochondrial length n ≥ 5 regions of interest per n ≥
3 sections per animal were analyzed and quantified by operators blinded
to the treatment using ImageJ v. 2.1.0/1.53c (Fiji) software.
Flow cytometry
Flow cytometry analysis was performed on fresh tissues. Isolated spinal
cords were kept in a cold IMDM medium supplemented with 5% FBS, 1%
GlutaMAX, and 1% pen/strep and mechanically minced. Samples were
then enzymatically digested at 37 °C for 30min with a cocktail of 2 mg/ml
collagenase IV, 0.2 mg/ml dispase, and 0.1 mg/ml DNase I in supplemented
IMDM. Then, the cell suspension was homogenized by passaging through
40 µm cell strainers using 10ml of supplemented IMDM for sample. For
myelin removal, the suspension was mixed with 90% isotonic Percoll
diluted in PBS 10× and then centrifuged for 20min at 800×g. Cell pellet
was resuspended in cold buffer (MACS BSA diluted in autoMACS rinsing
solution) and centrifuged twice at 4 °C for 5 min at 300g, resuspending
pellet with cold buffer and flow cytometry staining buffer respectively,
obtaining 1,000,000 cells/100 µl/sample. Samples were finally incubated for
15min at 4 °C with the following monoclonal antibodies: anti-mouse CD45
(Miltenyi Biotech, Cat#130-110-802, RRID: AB_2658222), CD11b (Miltenyi
Biotech, Cat#130-113-803, RRID: AB_2819369), F4/80 (Biolegend,
Cat#123118, RRID: AB_893477), Ly-6G (Miltenyi Biotech, Cat#130-117-500,
RRID: AB_2727967), CCR2 (Miltenyi Biotech, Cat#130-117-548, RRID:
AB_2727981), CX3CR1 (Biolegend, Cat#149006, RRID: AB_2564315),
CD206 (Biolegend, Cat#141717, RRID: AB_2562232), and CD80 (Miltenyi
Biotech, Cat#130-116-462, RRID: AB_2727559) antibodies.
In all experiments, viobility fixable dye (Miltenyi Biotech, Cat#130-109-816)
was used to label dead cells. Data were collected on a MACSQuant Analyzer
(Miltenyi Biotech) and analyzed using Flowlogic software (Miltenyi Biotech).
Data analysis was performed as described elsewhere [49, 50]. Briefly, it
was based on a multi-step bioinformatics approach: (1) reading FCS data;
(2) building a self-organizing map (SOM) for clustering; (3) performing a
dimensionality reduction through principal component analysis (PCA) and
uniform manifold approximation and projection (UMAP); (4) perform a
supervised identification of each cluster; (5) performing a statistical analysis
on the abundance of each population according to their origin (ANOVA).
Besides the characterization of the myeloid compartment, the unsuper-
vised clustering algorithm identified two different lymphocytes clusters:
one with strong positivity for HLA-DR, that we identified as B cells and a
second one that includes residual T and NK cells (T/NK) which cannot be
separated with the current markers panel.
Tissue preparation and HPLC analysis of metabolites
All animals of the three groups (controls, CTB-Sap vehicle, and CTB-Sap
clobetasol) underwent the same surgical procedure to remove spinal cord
and GMs. Once removed, tissues were immediately immersed in liquid
nitrogen, weighed and deproteinized by homogenization in ice-cold HPLC-
grade CH3CN+ 10mM KH2PO4 pH 7.40 (3:1; v-v), using an Ultra-Turrax
(Janke and Kunkel, Staufen, Germany) at 24,000 rpm/min for 90 s [51–55].
Following centrifugation at 20,690×g for 10 min at 4 °C, clear supernatants
were supplemented with HPLC-grade chloroform, vigorously agitated and
centrifuged for 5 min in a top-bench centrifuge at the maximal speed. The
upper aqueous phase was used for the HPLC analyses of metabolites. The
simultaneous separation and quantification of high-energy phosphates,
oxidized and reduced nicotinic coenzymes, purines, pyrimidines, antiox-
idants, oxidative/nitrosative stress biomarkers and N-acetylaspartate (NAA)
was performed as described in detail elsewhere. Amino acids (AA) and
amino group-containing compounds (AGCC) were separated and quanti-
fied according to chromatographic conditions previously set up in our
laboratory. In both cases, the HPLC apparatus consisted of a Spectra
System P4000 pump, connected to a Hypersil C-18 250 × 4.6 mm, 5 µm
particle size column (provided with its own guard column) and to a highly
sensitive UV6000 LP diode array detector equipped with a 5 cm light path
flow cell (ThermoFisher Scientific, Rodano, Milano, Italy). Overall, the two
analyses allowed measuring the concentrations of 61 water-soluble low
molecular weight compounds in tissue extracts, thanks to the comparisons
with appropriate ultrapure standard mixtures with known concentrations.
Principal components analysis
Principal components analysis (PCA) was performed on spinal cord and GMs
metabolites data. Explained variances and the quality of representation of the
variables on the factor map expressed as square cosine (Cos2) are shown. PCA
is expressed as a biplot of variables and key-colored arrows representing each
variable are also shown. Analyses were carried out using the RStudio software
(Version 1.0.153, for Mac), fitted with corr plot, FactoMineR, and Factoextra
packages for computing and visualizing PCA diagrams.
Human gene expression
For human ALS data, we used the NCBI Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/geo/) to select n= 10 healthy and
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n= 10 ALS patients cervical spinal cord transcriptome dataset (GSE26927)
analyzing the expression levels of n= 6 selected genes (i.e. PTCH1, SMO,
SHH, GLI2, GLI1, and GLI3). Mesh terms “Spinal Cord”, “ALS” and “Human”
were used to identify potential datasets of interest. The dataset selected
was downloaded and analyzed using MultiExperiment Viewer (MeV)
software. Statistical analysis was performed using GraphPad Prism software
version 5.00 for Mac and MeV software. Interaction network of SHH
signaling pathway was obtained using String (https://string-db.org/) online
tool for gene ontology and KEGG enrichment analysis.
Quantification and statistical analysis
The sample size for each experiment is reported in figure legends. No
statistical methods were used to predetermine sample sizes, but our
sample sizes were similar to those reported in previous publications
[15, 18, 48, 56]. Mice were randomly assigned to experimental groups. No
data points or animals were excluded from the analysis. For statistical
analyses, a two-tailed unpaired Student’s t-test was used for comparison of
n= 2 groups. For comparison of n ≥ 3 groups, one-way or two-way analysis
of variance (ANOVA), or repeated-measures ANOVA with Holm–Sidak post-
hoc test for multiple comparisons were used where appropriate. Data are
presented as the mean ± standard error of the mean (SEM) unless
otherwise stated. Data analysis was performed using GraphPad Prism
software version 5.00 or RStudio software version 1.0.153. A value of p <
0.05 was considered statistically significant and symbols used to indicate
statistical differences are described in figure legends.
DATA AVAILABILITY
The datasets used and/or analyzed during the current study are available from the
corresponding author on reasonable request.
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